Loading
A phase 2 trial in lung cancer, run by Mark Vincent, now recruiting.
Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge is a phase 2, interventional study registered as NCT04335292 by Mark Vincent, with a registry enrolment figure of 200 participants, started 2021-01-06 and due to reach its primary completion in 2026-06-01. Interventions recorded: Osimertinib First-Line; Platinum + Pemetrexed Chemotherapy Second-Line; Osimertinib Third-Line. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Objective Response Rate according to Response Evaluation Criteria in Solid Tumors version 1.1. Lung eligibility wording from the registry: "* Pathologically proven advanced non-small cell lung cancer (i". Sites: Canada. No results are recorded here; the registry entry is the source.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), AstraZeneca and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), AstraZeneca and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.